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Outpatient Parenteral Antimicrobial Therapy Practices among
Adult Infectious Disease Physicians
Michael A. Lane, MD;1 Jonas Marschall, MD;1 Susan E. Beekmann, MPH;2 Philip M. Polgreen, MD;2
Ritu Banerjee, MD;3 Adam L. Hersh, MD;4 Hilary M. Babcock, MD1
objective. To identify current outpatient parenteral antibiotic therapy practice patterns and complications.
methods. We administered an 11-question survey to adult infectious disease physicians participating in the Emerging Infections Network
(EIN), a Centers for Disease Control and Prevention–sponsored sentinel event surveillance network in North America. The survey was
distributed electronically or via facsimile in November and December 2012. Respondent demographic characteristics were obtained from
EIN enrollment data.
results. Overall, 555 (44.6%) of EIN members responded to the survey, with 450 (81%) indicating that they treated 1 or more patients
with outpatient parenteral antimicrobial therapy (OPAT) during an average month. Infectious diseases consultation was reported to be
required for a patient to be discharged with OPAT by 99 respondents (22%). Inpatient (282 [63%] of 449) and outpatient (232 [52%] of
449) infectious diseases physicians were frequently identified as being responsible for monitoring laboratory results. Only 26% (118 of 448)
had dedicated OPAT teams at their clinical site. Few infectious diseases physicians have systems to track errors, adverse events, or “near
misses” associated with OPAT (97 [22%] of 449). OPAT-associated complications were perceived to be rare. Among respondents, 80%
reported line occlusion or clotting as the most common complication (occurring in 6% of patients or more), followed by nephrotoxicity
and rash (each reported by 61%). Weekly laboratory monitoring of patients who received vancomycin was reported by 77% of respondents
(343 of 445), whereas 19% of respondents (84 of 445) reported twice weekly laboratory monitoring for these patients.
conclusions. Although use of OPAT is common, there is significant variation in practice patterns. More uniform OPAT practices may
enhance patient safety.
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Over the past 30 years, outpatient parenteral antimicrobial
therapy (OPAT) has gained in popularity as a cost-effective
strategy for treating a variety of infectious diseases, including
skin and soft-tissue infections,1,2 osteomyelitis,3,4 prosthetic
joint infections,5,6 and endocarditis.7 In a 2006 survey of in-
fectious disease (ID) physicians, 94% indicated that patients
are commonly set up for OPAT at hospital discharge.8 In
addition to patients’ preference for being treated outside the
hospital setting,9 there are clear cost savings associated with
OPAT. Use of OPAT is significantly less expensive than con-
tinued inpatient care.10-12
In 2004, the Infectious Disease Society of America (IDSA)
published practice guidelines suggesting standards for OPAT
practices. These guidelines provide recommendations on pa-
tient evaluation and selection for OPAT services, antibiotic
selection and administration, OPAT team structure, and lab-
oratory monitoring.13 A survey of ID physicians, conducted
before the publication of these guidelines, revealed diverse
OPAT practices.8 Little is known about OPAT practice pat-
terns, complication rates, and safety systems since the pub-
lication of these guidelines. The aim of this study was to
survey adult ID physicians on their current OPAT practices.
methods
The Emerging Infections Network (EIN) is a network of ID
physicians in North America who provide care to adult and
pediatric patients. The network was established in 1995 by
the Centers for Disease Control and Prevention (CDC) to
establish a provider-based emerging infections sentinel net-
work.14 The network is also used for surveys of current knowl-
edge and practices of providers. This survey was sent elec-
tronically or via facsimile to the 1,244 EIN members who
provide care to adult patients. The survey was conducted from
November to December 2012. After the survey distribution,
email reminders were sent to nonrespondents 2 and 4 weeks
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after the initial invitation. The survey consisted of brief in-
troductory text and 11 questions. Survey questions addressed
OPAT practice patterns and safety issues. Participants were
asked about their participation in OPAT services and the role
of ID consultation before patient discharge or placement of
a vascular catheter for designated OPAT recipients. Partici-
pants were also asked about who was responsible for mon-
itoring and acting upon laboratory results from patients re-
ceiving OPAT. Respondents were queried on their perceptions
of the frequency and consequences of OPAT-related compli-
cations, including laboratory abnormalities, catheter-associ-
ated complications, and the development of Clostridium dif-
ficile or bloodstream infections. One question focused on
barriers to providing safe OPAT services to patients. Finally,
participants were asked to indicate the frequency of labora-
tory monitoring during OPAT for several frequently used
antibiotics. The survey may be found at http://ein.idsociety
.org/surveys/survey/62/. Differences in frequencies were an-
alyzed for statistical significance using x2 tests, Student t test,
and Mann-Whitney U test as appropriate. A P value of less
than .05 was considered to be statistically significant.
results
Overall, 555 (44.6%) of 1,244 physicians participating in the
EIN responded to the survey. Respondents came from all US
census regions.15 Response rates were similar across all census
regions. Respondents were significantly more likely than non-
respondents to have 15 years or more of ID experience
( ). EIN members with 25 years or more of expe-P ! .0001
rience were the largest group of respondents (150 [55%] of
274), followed by those with 15–24 years of experience (147
[50%] of 292).
Among respondents, 105 (19%) did not provide care to
any patients discharged with OPAT in an average month.
Among those who did manage patients who were receiving
OPAT, monthly patient volume varied widely; 114 respon-
dents (20%) managed 1–5 patients/month, 214 respondents
(39%) managed 6–15 patients/month, 80 respondents (14%)
managed 16–25 patients/month, and 42 respondents (8%)
managed more than 25 patients/month. Respondents ranked
the patient’s home as the most common location for receiving
OPAT, followed by infusion centers, dialysis centers, and
emergency rooms.
Twenty-two percent of respondents reported that ID con-
sultation is required to discharge any patient who is receiving
intravenous antibiotics. Of those requiring ID consultation
to discharge a patient with OPAT, only 28 (28%) required ID
consultation to approve vascular access placement for OPAT.
The inpatient (63%) and outpatient (52%) ID physicians were
the most commonly identified as being responsible for mon-
itoring and acting upon laboratory results. Ninety-four re-
spondents (21%) indicated that the patient’s primary care
physician was responsible for monitoring laboratory results.
Dedicated OPAT teams whose primary job is to monitor pa-
tients receiving OPAT were uncommon, with 118 (26%) re-
porting this service at their primary hospital or clinic. Re-
spondents providing OPAT services to 16 or more patients
per month were more likely to have a dedicated OPAT team,
compared with lower-volume providers (40% vs 21%; P !
). Lack of a dedicated OPAT team was the single most.001
common barrier reported to providing safe OPAT services
(median rank, 2), followed by the large number of locations
at which patients receive OPAT, communication issues, and
volume of laboratory results (median rank, 3).
Only 97 (22%) of the respondents have a system to track
the frequency of errors, adverse events, or “near misses” as-
sociated with OPAT. Those providing OPAT services to more
than 16 patients per month were more likely to have error-
reporting systems than were lower-volume providers (32%
vs 18%; P p .023). Line occlusion or clotting, rash, and
nephrotoxicity were the most commonly reported compli-
cations associated with OPAT (Figure 1). Respondents indi-
cated that patients commonly required line exchange or re-
moval or change in antibiotic therapy because of
complications from OPAT; hospitalization for OPAT com-
plications was less common (Figure 2). Over the past 5 years,
98 (22%) and 214 (48%) of the respondents reported OPAT-
related complications to be less frequent or unchanged, re-
spectively. A minority (67 [15%]) reported OPAT-related
complications to be more frequent than 5 years ago. Although
there is some variation, weekly laboratory monitoring was
reported to be the most common practice for several common
antibiotics (Table 1).
discussion
We report the results of a survey of a large network of adult
ID physicians regarding their experiences providing OPAT.
We found that the use of OPAT is common among ID phy-
sicians, with over 80% of respondents discharging 1 or more
patients with OPAT during an average month. We found
significant variability in the involvement of ID physicians in
selecting patients for OPAT, practice infrastructure, and lab-
oratory monitoring practices.
Selecting patients who would benefit from OPAT is critical
to treatment success. International OPAT guidelines recom-
mend careful review of patients who might be appropriate
for OPAT.13,16 Patients discharged with OPAT must be med-
ically stable to receive continued treatment outside the in-
patient hospital setting. In addition, IDSA guidelines rec-
ommend an assessment of the patient and caregivers who
will be responsible for administering the medications and
caring for vascular access devices.13 In addition to assessing
the patient and caregiver’s ability to provide daily OPAT care
at home, formal ID consultation facilitates the appropriate
selection of antibiotic therapy. Sharma et al17 found that re-
quiring ID consultation before discharge with OPAT fre-
quently altered the patient’s care and resulted in a significant
cost savings. At the Cleveland Clinic, ID consultation is re-
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figure 1. Number of respondents reporting perceived frequency of specified outpatient parenteral antimicrobial therapy complications.
DVT, deep vein thrombosis.
quired before patient discharge with OPAT. In a study of 263
candidates for OPAT, ID consultation resulted in optimization
of the antibiotic treatment regimen or significant alterations
in the patient’s assessment in 84% and 52%, respectively, of
patients evaluated by OPAT physicians. Additionally, OPAT
was determined to be unnecessary in 27% of patients eval-
uated, almost half of whom were deemed not to need any
antibiotic therapy at all following discharge.18 Although these
studies demonstrate significant benefit to patients, few hos-
pitals require ID consultation before discharge. In our study,
only 22% of respondents indicated that ID consultation was
required to initiate OPAT. Our results suggest that there are
significant opportunities for improvement in antibiotic stew-
ardship through the use of routine ID consultation before
OPAT initiation.
Additionally, our survey found that a wide variety of pro-
viders are responsible for monitoring and acting upon lab-
oratory results for patients treated with OPAT, including in-
patient ID physicians (reported by 63% of respondents),
outpatient ID physicians (52% of respondents), patient pri-
mary care physicians (21% of respondents), and pharmacists
(9% of respondents). Although it is possible that some var-
iation may be attributable to different models of OPAT de-
livery,19 our findings suggest a lack of consensus regarding
standard processes to ensure that patients receive appropriate
monitoring after hospital discharge. Only 26% of respondents
indicated that their primary hospital or clinic had a specified
provider or team whose primary purpose was to monitor
patients receiving OPAT; it is possible that some clinical prac-
tices use various personnel to perform these duties even
though it is not their primary role. Respondents reported
many barriers to providing safe OPAT services. The lack of
dedicated personnel was the single most common barrier
reported by respondents. Although IDSA guidelines recom-
mend a multidisciplinary team to coordinate care and mon-
itor laboratory results, our study suggest that these recom-
mendations may be poorly implemented in current practice.
Although earlier surveys of ID physicians suggest OPAT
complications are common, there are limited data on the
frequency of OPAT-related adverse events or hospital re-
admission.8 In a retrospective study of 302 courses of OPAT,
significant adverse events were noted in 25%. Renal failure
was the most common adverse event, occurring in 7% of
OPAT courses.20 Among patients with osteomyelitis treated
with OPAT, 5% experienced some adverse event.21 This OPAT
registry also demonstrated that 25.2% of patients treated with
vancomycin experienced a vancomycin or intravenous line–
related adverse event.22 Other reports have shown significant
rates of decreased renal function, as high as 3.08 patients per
1,000 therapy-days among patients treated with select anti-
biotics.23 Hospital readmission because of complications as-
sociated with OPAT therapy occurs in 12%–16% of pa-
tients.6,24 In our study, respondents reported line occlusion
or clotting, rash, and nephrotoxicity occur commonly, al-
though most believe there has been no change in the fre-
quency of OPAT-related complications over the past 5 years.
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figure 2. Number of respondents reporting perceived frequency of specified consequences of outpatient parenteral antimicrobial therapy
complications.
table 1. Laboratory Antibiotic Monitoring Frequency
No. (%) of respondents,
by no. of times per week
that antibiotic is monitored
Antibiotic !1 1 2 3 13
Total
respondents
Daptomycin 33 (8) 385 (88) 20 (5) 1 (0) 0 (0) 439
Vancomycin 16 (4) 343 (77) 84 (19) 2 (0) 0 (0) 445
Oxacillin-nafcillin 38 (9) 385 (87) 17 (4) 2 (0) 0 (0) 442
Cephalosporins 44 (10) 384 (87) 11 (2) 1 (0) 1 (0) 441
Carbapenems 44 (10) 388 (87) 12 (3) 0 (0) 0 (0) 444
Amphotericin 22 (5) 98 (24) 194 (47) 91 (22) 10 (2) 415
Aminoglycosides 23 (5) 130 (30) 247 (57) 31 (7) 4 (1) 435
However, despite the frequency of these complications, fewer
than one-quarter have systems to track the frequency of er-
rors, adverse events, or “near-misses” associated with OPAT.
Given the widespread lack of reporting systems or registries,
it is possible that error rates reported by respondents un-
derestimate the true number of patients who experience harm
while treated with OPAT.
Although weekly laboratory monitoring was most common
for many antibiotics, our results demonstrated some vari-
ability in practice. Vancomycin use has become more com-
mon as rates of methicillin-resistant Staphylococcus aureus
infection have increased among hospitalized patients. Van-
comycin-associated nephrotoxicity rates have been reported
to vary widely from 5%–35%.25 Clinical guidelines on van-
comycin use suggest once weekly monitoring for hemody-
namically stable patients;26 however, these guidelines do not
address the safety of high vancomycin dose strategies that
target a trough concentration of 15–20 mg/L. A subsequent
meta-analysis demonstrated an increased risk of nephrotox-
icity among patients with vancomycin trough greater than or
equal to 15 mg/L compared with those with a trough less
than 15 mg/L (odds ratio, 2.67 [95% confidence interval,
1.95–3.65]).27 Most respondents in our study report moni-
toring laboratories on a weekly basis for patients treated with
vancomycin. However, more frequent laboratory monitoring,
favored by 86 (19%) of 445 respondents, may allow for early
identification and intervention for patients who develop
nephrotoxicity.
This study has several limitations that may limit the gen-
eralizability of the results. Although we had more than 550
respondents, these respondents may not be representative of
the entire ID community. Additionally, a significant number
of respondents indicated they were not required to be in-
volved in the management of patients discharged with OPAT.
Because our survey targeted only EIN members, it is possible
that OPAT practices and complication rates identified in our
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survey are not representative of patients discharged with
OPAT by other medical providers. Additionally, recall bias is
an inherent limitation of surveys.
Although OPAT has been used for decades to successfully
treat a wide array of infectious diseases, our study demon-
strates there is tremendous variability in practice patterns
among physicians who provide OPAT services. With increas-
ing focus on improving the quality of medical care and re-
ducing hospital readmissions, standardization of OPAT prac-
tices has the potential to provide significant benefit to
patients. To improve clinical outcomes, robust tracking sys-
tems or OPAT registries will need to be developed to support
evidence-based practices and monitor individual patient
outcomes.
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